The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...

Researchers have identified chromosomal instability in circulating tumour cells as a prognostic and predictive biomarker in ...

HER2CLIMB-05 trial evaluated Tukysa in combination with Herceptin and Perjeta for HER2-positive metastatic breast cancer, ...

At the San Antonio Breast Cancer Symposium (SABCS), investigators outlined the rationale and design of the ERADICATE, a first ...

Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...

In the PREFER trial, researchers aimed to investigate and assess the safety of strategies for fertility preservation in ...

The HER2CLIMB-05 study assessed the efficacy and safety of adding tucatinib to maintenance therapy with trastuzumab/pertuzumab in patients with HER2+ metastatic breast cancer.

Glomus tumours are uncommon, typically benign neoplasms of specialised dermal thermoregulatory structures known as glomus ...

† Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27515, United States ∥ Lineberger Comprehensive Cancer Center, University of North Carolina at ...

As per DelveInsight estimates, the total prevalent population of prostate cancer in the 7MM was nearly 8,241,000 cases in 2023. These cases are projected to increase during the forecast period, i.e., ...

STING–type-I interferon pathway regulates the immunogenicity of several cancer types, including head and neck squamous cell carcinoma. Here the authors describe that glutamine metabolism in the tumour ...